These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34126710)

  • 21. Amyloidosis: a case series and review of the literature.
    Senecal JB; Abou-Akl R; Allevato P; Mazzetti I; Hamm C; Parikh R; Woldie I
    J Med Case Rep; 2023 Apr; 17(1):184. PubMed ID: 37081462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.
    Posadas-Martinez ML; Aguirre MA; Brulc E; Saez MS; Sorroche P; Machnicki G; Fernandez M; Nucifora EM
    PLoS One; 2022; 17(10):e0274578. PubMed ID: 36301970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of immunoglobulin light chain (primary or AL) amyloidosis.
    Gertz MA; Buadi FK; Hayman SR
    Oncology (Williston Park); 2011 Jun; 25(7):620-6. PubMed ID: 21888261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloidosis of the Heart and Kidney.
    Adrogue HE
    Methodist Debakey Cardiovasc J; 2022; 18(4):27-33. PubMed ID: 36132587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
    Gertz MA
    Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury.
    Crees ZD; Stockerl-Goldstein K
    Am J Med; 2022 Apr; 135 Suppl 1():S49-S52. PubMed ID: 35081378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future Developments in Light Chain Amyloidosis Management.
    Rodriguez M; Lenihan D; Merlini G
    Am J Med; 2022 Apr; 135 Suppl 1():S53-S57. PubMed ID: 35081388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis.
    Martins CO; Lezcano C; Yi SS; Landau HJ; Chapman JR; Dogan A
    Haematologica; 2018 Dec; 103(12):e610-e612. PubMed ID: 30262557
    [No Abstract]   [Full Text] [Related]  

  • 30. Ptosis and macroglossia in a woman with systemic light-chain amyloidosis.
    Hsiao PJ; Chang YC; Tsao YH; Wu KL; Kao YH; Chan JS; Wang CH; Lin YY; Chuu CP; Lin YS
    Clin Chim Acta; 2019 Jul; 494():112-115. PubMed ID: 30905590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem cell transplantation for immunoglobulin light chain amyloidosis.
    Sher T; Gertz MA
    Curr Probl Cancer; 2017; 41(2):129-137. PubMed ID: 28457657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropathy Associated with Systemic Amyloidosis.
    Kaku M; Berk JL
    Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AL amyloidosis: advances in diagnostics and treatment.
    Ryšavá R
    Nephrol Dial Transplant; 2019 Sep; 34(9):1460-1466. PubMed ID: 30299492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis.
    Schwotzer R; Flammer AJ; Gerull S; Pabst T; Arosio P; Averaimo M; Bacher VU; Bode P; Cavalli A; Concoluci A; Dirnhofer S; Djerbi N; Dobner SW; Fehr T; Garofalo M; Gaspert A; Heimgartner R; Hübers A; Jung HH; Kessler C; Knöpfel R; Laptseva N; Manka R; Mazzucchelli L; Meyer M; Mihaylova V; Monney P; Mylonas A; Nkoulou R; Pazhenkottil A; Pfister O; Rüfer A; Schmidt A; Seeger H; Stämpfli SF; Stirnimann G; Suter T; Théaudin M; Treglia G; Tzankov A; Vetter F; Zweier M; Gerber B
    Swiss Med Wkly; 2020 Nov; 150():w20364. PubMed ID: 33277911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.
    Muchtar E; Dispenzieri A; Gertz MA; Kumar SK; Buadi FK; Leung N; Lacy MQ; Dingli D; Ailawadhi S; Bergsagel PL; Fonseca R; Hayman SR; Kapoor P; Grogan M; Abou Ezzeddine OF; Rosenthal JL; Mauermann M; Siddiqui M; Gonsalves WI; Kourelis TV; Larsen JT; Reeder CB; Warsame R; Go RS; Murray DL; McPhail ED; Dasari S; Jevremovic D; Kyle RA; Lin Y; Lust JA; Russell SJ; Hwa YL; Fonder AL; Hobbs MA; Rajkumar SV; Roy V; Sher T
    Mayo Clin Proc; 2021 Jun; 96(6):1546-1577. PubMed ID: 34088417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.
    Baker KR
    Methodist Debakey Cardiovasc J; 2022; 18(2):27-35. PubMed ID: 35414848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
    Hu Y; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis.
    Ravichandran S; Law S; Mahmood S; Wisniowski B; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
    Leukemia; 2022 Apr; 36(4):1180-1184. PubMed ID: 34987193
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral Nervous System Involvement.
    Thaisetthawatkul P; Dyck PJB
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1091-1098. PubMed ID: 33099426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.